ArticleJournal of thoracic disease2025
Efficacy and survival of photodynamic treatment for tracheal adenoid cystic carcinoma: a two-center retrospective analysis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tracheal adenoid cystic carcinoma (TACC) is a rare malignant tumor with limited treatment options for unresectable cases. Although case reports have indicated the value of photodynamic therapy (PDT), its efficacy, survival outcomes, and prognostic factors remain poorly characterized. This two-center retrospective study aimed to evaluate the long-term outcomes of patients with TACC treated with PDT and to identify predictors of treatment response. Methods: A retrospective analysis was conducted on 39 patients with TACC who received continuous PDT treatment in two hospitals from August 2011 to September 2023. All patients were intravenously injected with hematoporphyrin derivative (HpD) at a dose of 2 mg/kg and treated 48 hours later. The therapeutic effect was evaluated according the 2019 efficacy evaluation standard for PDT for respiratory tumors. The primary endpoints were overall survival (OS) and progression-free survival (PFS), while the secondary endpoints included objective response rate (ORR) and safety. The prognostic factors were analyzed via a Cox regression model. Results: The study included 39 patients, with a mean age of 47.51±14 years (range, 19-79 years). The most recent efficacy evaluation of 39 patients, conducted 1 month after PDT treatment, showed complete response (CR) in 5 patients, partial response (PR) in 25 patients, and progressive disease (PD) in 9 patients. Both OS and PFS were significantly longer in the PR group than in the PD group (OS: P=0.008; PFS: P=0.005). The 5-, 10-, and 15-year survival rates for patients were 73.2%, 64.1%, and 42.7%, respectively. Only 7 patients experienced complications. Univariate Cox regression analysis indicated that the age and treatment interval were significant risk factors for the emergence of TACC (P=0.03). Conclusions: We found that PDT for patients with TACC achieved satisfactory clinical efficacy and safety, resulting in longer survival and fewer complications. Moreover, treatment interval and age were risk factors for the development of TACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.